Copy to clipboard 
Vericel reported 4Q21 orthopedic sales of $37.4 million, +7.7% vs. 4Q20. For the full year, the company generated $111.6 million in MACI sales, +18.1% vs. the prior year.
Vericel anticipates MACI sales between $132 million and $141 million for 2022, representing growth between +18% and +26%. The wide range in guidance is driven by uncertainty around backlog recovery timing. By the end of the fourth quarter, Vericel estimated its backlog at $10 million but the current market environment could slow the recapture of those cases.
Regardless, the company is making investments to sustain the growth of MACI for several years to come. A new manufacturing facility in the Boston area is slated to come online in 2025 and increase Vericel’s capacity to sustain growth.
Additionally, the company is starting to manage the lifecycle of MACI by developing an arthroscopic delivery method and new ankle indication for the product. At the conclusion of those projects, Vericel estimates that its addressable market will be $3 billion.
Company CEO Nick Colangelo said, “We certainly expect to be in the 20-plus percent compounded annual growth rate as a product portfolio through mid-decade. And then, given the fact that these are large underpenetrated markets, we think there’s growth ahead for multiple years.”
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $37.4 | $34.7 | $2.7 | 7.7% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $111.6 | $94.4 | $17.1 | 18.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.6 | |
| Cost of Sales | $13.6 | 28.5% |
| General and Admin | $26.0 | 54.6% |
| R & D | $0.0 | 0% |
| Other | ($0.4) | (0.8%) |
| Net Earnings | $4.5 | 9.5% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Vericel reported 4Q21 orthopedic sales of $37.4 million, +7.7% vs. 4Q20. For the full year, the company generated $111.6 million in MACI sales, +18.1% vs. the prior year.
Vericel anticipates MACI sales between $132 million and $141 million for 2022, representing growth between +18% and +26%. The wide range in guidance is driven by...
Vericel reported 4Q21 orthopedic sales of $37.4 million, +7.7% vs. 4Q20. For the full year, the company generated $111.6 million in MACI sales, +18.1% vs. the prior year.
Vericel anticipates MACI sales between $132 million and $141 million for 2022, representing growth between +18% and +26%. The wide range in guidance is driven by uncertainty around backlog recovery timing. By the end of the fourth quarter, Vericel estimated its backlog at $10 million but the current market environment could slow the recapture of those cases.
Regardless, the company is making investments to sustain the growth of MACI for several years to come. A new manufacturing facility in the Boston area is slated to come online in 2025 and increase Vericel’s capacity to sustain growth.
Additionally, the company is starting to manage the lifecycle of MACI by developing an arthroscopic delivery method and new ankle indication for the product. At the conclusion of those projects, Vericel estimates that its addressable market will be $3 billion.
Company CEO Nick Colangelo said, “We certainly expect to be in the 20-plus percent compounded annual growth rate as a product portfolio through mid-decade. And then, given the fact that these are large underpenetrated markets, we think there’s growth ahead for multiple years.”
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $37.4 | $34.7 | $2.7 | 7.7% |
| FY20 | FY19 | $ Chg | % Chg | |
|---|---|---|---|---|
| Orthobiologics | $111.6 | $94.4 | $17.1 | 18.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $47.6 | |
| Cost of Sales | $13.6 | 28.5% |
| General and Admin | $26.0 | 54.6% |
| R & D | $0.0 | 0% |
| Other | ($0.4) | (0.8%) |
| Net Earnings | $4.5 | 9.5% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
